PDCD1 and melanoma: Regarding combinatorial therapies that target adenosine signaling to improve the response to immunotherapies, oral administration of A2AR antagonists reduces PD-1 and LAG-3 expression on activated CD8+CD44+ T cells within tumor-draining lymph nodes (dLNs) and Tregs infiltrating tumors in a mouse melanoma model (208).